Tradestie Institutional Equity Comparison Engine

BOLD vs OBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BOLD Overall Edge

BOLD Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Boundless Bio, Inc. Common Stock (BOLD) driven by superior Growth & Margin, Momentum & Technical while OBIO counters with relative strength in Options & Structure. Fundamentally, BOLD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus OBIO at N/M Forward P/E and -195.4% operating margin (-89.4% YoY). In options structure, BOLD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against OBIO sits in CONSOLIDATION (21st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BOLD N/M vs OBIO N/M Fwd P/E
Growth & Margin Winner BOLD
Op Margin 0.0% vs -195.4% ยท YoY +0.0% vs -89.4%
Momentum & Technical Winner BOLD
1Y +101.7% vs +41.2% ยท 52W Pos 62% vs 72%
Options & Structure Winner OBIO
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (21st %ile IV)
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
1M Return -4.92%
1Y Return +101.74%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.58
-6.0% 1D
Market Cap $550.9M
1M Return +20.29%
1Y Return +41.2%
Forward P/E N/M
Unified AI Score
41.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 64.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BOLD +101.74% OBIO +41.2% Spread: +60.54 pp (BOLD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BOLD TTM Op. Margin: 0.0% OBIO TTM Op. Margin: -195.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BOLD vs OBIO. Trailing 12-month operating profitability (BOLD 0.0% vs OBIO -195.4%) and valuation multiples (BOLD N/M vs OBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BOLD (5) vs OBIO (3)
Institutional Metric BOLD OBIO Criterion Row Winner
Market Capitalization Scale $56.2M $550.9M Larger Scale OBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -89.4% Higher Growth BOLD
Operating Margin (TTM) Profitability 0.0% -195.4% Higher Margin BOLD
Net Profit Margin Profitability 0.0% -182.5% Higher Margin BOLD
Return on Equity (ROE) Capital Efficiency -64.6% -182.3% Higher ROE BOLD
52-Week Range Position Momentum 62% ($1โ€“$3) 72% ($3โ€“$8) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime -0.08ฮฒ ยท 28% Vol 1.18ฮฒ ยท 88% Vol Lower Realized Risk BOLD
Unified Institutional Score Composite Signal 36.8 / 100 (SELL) 41.1 / 100 (SELL) Higher Composite OBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BOLD vs OBIO Buy Guide
BOLD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BOLD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OBIO CONSOLIDATION
36d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 21st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BOLD nor OBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.